ArticleNature communications2022
Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Multi-cancer early detection tests for general population screening: a systematic literature review.Health technology assessment (Winchester, England) · 2025Pooled it
- Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study.Cell reports. Medicine · 2026Article
- Nano-formulations in therapeutic strategies targeting cancer ferroptosis.Journal of pharmaceutical analysis · 2026Review
- Machine learning-driven cancer diagnostics with improved robustness and interpretability.Chemical science · 2026Review
- Gold-Functionalized Multilayer Heterojunction Microarchitectures Enable High-Fidelity Serum Metabolite Profiling for Skin Cancer Subtype Classification.Small methods · 2026Article
- Metabolomics-assisted evaluation of differences and clinical value between ablation and surgical treatment for lung adenocarcinoma.Frontiers in oncology · 2026Article
- Multi-cancer early detection: from promise to practice and the next frontier.Cancer biology & medicine · 2025Article
- Plasma protein profiling predicts cancer in patients with non-specific symptoms.Nature communications · 2025Article
- Prediction of neoadjuvant chemotherapy efficacy in patients with HER2-low breast cancer based on ultrasound radiomics.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.Science bulletin · 2025Review
- Reply to: comment on "Early cancer detection by serum biomolecular fingerprinting spectroscopy with machine learning".Light, science & applications · 2025Article
- Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine.Chemical reviews · 2024Review
- Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.Frontiers in immunology · 2024Article
- Metabolomics unveils the exacerbating role of arachidonic acid metabolism in atherosclerosis.Frontiers in molecular biosciences · 2024Article
- Engineering the MoSAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- Review
- Clinical Scores, Biomarkers and IT Tools in Lung Cancer Screening-Can an Integrated Approach Overcome Current Challenges?Cancers · 2023Review
- Neighboring mutation-mediated enhancement of dengue virus infectivity and spread.EMBO reports · 2022Article
- Nodular and Micronodular Basal Cell Carcinoma Subtypes Are Different Tumors Based on Their Morphological Architecture and Their Interaction with the Surrounding Stroma.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As cancer is increasingly considered a metabolic disorder, it is postulated that serum metabolite profiling can be a viable approach for detecting the presence of cancer. By multiplexing mass spectrometry fingerprints from two independent nanostructured matrixes through machine learning for highly sensitive detection and high throughput analysis, we report a laser desorption/ionization (LDI) mass spectrometry-based liquid biopsy for pan-cancer screening and classification. The Multiplexed Nanomaterial-Assisted LDI for Cancer Identification (MNALCI) is applied in 1,183 individuals that include 233 healthy controls and 950 patients with liver, lung, pancreatic, colorectal, gastric, thyroid cancers from two independent cohorts. MNALCI demonstrates 93% sensitivity at 91% specificity for distinguishing cancers from healthy controls in the internal validation cohort, and 84% sensitivity at 84% specificity in the external validation cohort, with up to eight metabolite biomarkers identified. In addition, across those six different cancers, the overall accuracy for identifying the tumor tissue of origin is 92% in the internal validation cohort and 85% in the external validation cohort. The excellent accuracy and minimum sample consumption make the high throughput assay a promising solution for non-invasive cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.